Utilities of Botulinum Toxins in Dermatology and Cosmetology

In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to Food and Drug Administration (FDA) approval of each toxin for dystonia indications are reviewed, in addition to several studies highlighted by the AAN guidelines. The AAN guidelines for the use of BoNT in dystonia are compared with those of the European Federation of the Neurological Societies (EFNS), and common off-label uses for BoNT in dystonia are discussed. Toxins not currently FDA-approved for the treatment of dystonia are additionally reviewed. In the future, additional toxins may become FDA-approved for the treatment of dystonia given expanding research in this area.

Download Full-text

Electrical Stimulation of Injected Muscles to Boost Botulinum Toxin Effect on Spasticity: Rationale, Systematic Review and State of the Art

Toxins ◽

10.3390/toxins13050303 ◽

2021 ◽

Vol 13 (5) ◽

pp. 303

Author(s):

Alessandro Picelli ◽

Mirko Filippetti ◽

Giorgio Sandrini ◽

Cristina Tassorelli ◽

Roberto De Icco ◽

...

Keyword(s):

Systematic Review ◽

Electrical Stimulation ◽

Botulinum Toxin ◽

Current Literature ◽

Electric Stimulation ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Botulinum Toxins ◽

Stimulation Of

Botulinum toxin type A (BoNT-A) represents a first-line treatment for spasticity, a common disabling consequence of many neurological diseases. Electrical stimulation of motor nerve endings has been reported to boost the effect of BoNT-A. To date, a wide range of stimulation protocols has been proposed in the literature. We conducted a systematic review of current literature on the protocols of electrical stimulation to boost the effect of BoNT-A injection in patients with spasticity. A systematic search using the MeSH terms “electric stimulation”, “muscle spasticity” and “botulinum toxins” and strings “electric stimulation [mh] OR electrical stimulation AND muscle spasticity [mh] OR spasticity AND botulinum toxins [mh] OR botulinum toxin type A” was conducted on PubMed, Scopus, PEDro and Cochrane library electronic databases. Full-text articles written in English and published from database inception to March 2021 were included. Data on patient characteristics, electrical stimulation protocols and outcome measures were collected. This systematic review provides a complete overview of current literature on the role of electrical stimulation to boost the effect of BoNT-A injection for spasticity, together with a critical discussion on its rationale based on the neurobiology of BoNT-A uptake.

Download Full-text

A novel quantification method for measuring neutralizing antibodies against botulinum toxins in sera of toxin – Non-responsive patients

Toxicon ◽

10.1016/j.toxicon.2020.11.488 ◽

2021 ◽

Vol 190 ◽

pp. S68-S69

Author(s):

Minhee Shin ◽

Dongkyu Lee ◽

Nak-Kwan Sung ◽

Woonkyong Chung ◽

Junho Lee

Keyword(s):

Neutralizing Antibodies ◽

Botulinum Toxins ◽

Quantification Method

Download Full-text

Antibodies and vaccines against botulinum toxins: Available measures and novel approaches

Toxicon ◽

10.1016/j.toxicon.2020.11.473 ◽

2021 ◽

Vol 190 ◽

pp. S62

Author(s):

Christine Rasetti-Escargueil ◽

Emmanuel Lemichez ◽

Michel R. Popoff

Keyword(s):

Botulinum Toxins ◽

Novel Approaches

Download Full-text

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Toxins ◽

10.3390/toxins13020120 ◽

2021 ◽

Vol 13 (2) ◽

pp. 120

Author(s):

Emanuela Martina ◽

Federico Diotallevi ◽

Giulia Radi ◽

Anna Campanati ◽

Annamaria Offidani

Keyword(s):

Systematic Review ◽

Skin Diseases ◽

Meta Analysis ◽

Published Data ◽

Efficacy And Safety ◽

Botulinum Toxins ◽

Epidermolysis Bullosa Simplex ◽

Off Label ◽

Facial Erythema ◽

Notalgia Paresthetica

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

Download Full-text